Pinealon
Research OnlyAlso known as: EDR, Glu-Asp-Arg, Pinealon peptide, T-33 peptide
A synthetic tripeptide (Glu-Asp-Arg) developed by Russian researcher Vladimir Khavinson as a 'peptide bioregulator' claimed to support brain function. Part of a larger Russian research program on short peptides. Evidence comes almost exclusively from Russian publications with no independent Western replication. Not approved by any Western regulatory agency.
Research Statistics
Russian bioregulator with exclusively Khavinson institute research; no independent Western replication and neuroprotective chromatin-binding mechanism remains theoretical.
Research Dossier
Overview
What is Pinealon and what does the research say?
Mechanism of Action
The proposed mechanisms of Pinealon are based almost exclusively on Russian preclinical studies. No independent Western replication exists, and human mechanistic data is lacking.
How It Works (Simplified)
Pinealon is claimed to act through several pathways, though these remain largely unvalidated:
Claimed to suppress reactive oxygen species (ROS) and upregulate antioxidant enzymes like SOD and glutathione peroxidase in neuronal cells.
Proposed to delay ERK1/2 activation under oxidative stress, potentially protecting neurons from excitotoxicity-induced damage.
Khavinson theory claims DNA binding and gene expression modulation. This extraordinary claim lacks rigorous independent validation.
Claimed to reduce neuronal apoptosis and preserve dendritic spine density, though evidence is limited to single-laboratory Russian studies.
Scientific Pathways
ROS Suppression Pathway (Antioxidant - Partially Supported)
Pinealon → SOD/Glutathione peroxidase upregulation → ROS reduction
↓
Reduced oxidative damageERK1/2 Modulation Pathway (Cell Signaling - Emerging)
Pinealon → Delayed ERK1/2 activation → Modified stress response → Cell survivalKey Research: Khavinson V et al. (Russia, 2011) demonstrated ROS suppression in cerebellar granule cells. PMID:21978084
Important Limitations
- Nearly all studies from single research group (Khavinson laboratory, St. Petersburg)
- No independent Western replication of any findings
- DNA binding mechanism is extraordinary and unvalidated
- Translation to human physiology is completely unconfirmed
- Pharmacokinetics in humans not characterized
- Oral bioavailability likely very low (typical for peptides)
- Products are unregulated research chemicals with uncertain purity
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on limited preclinical data: Proposed antioxidant effects may begin. Russian cell studies show ROS suppression within hours to days of exposure. No human timeline data available. Oral bioavailability likely very low for this tripeptide.
Animal studies suggest ongoing neuroprotective signaling. ERK1/2 modulation observed in cell models within this timeframe. Translation to human effects is completely speculative and unvalidated.
Mouse studies showed dendritic spine density changes over several weeks. Long-term effects, optimal duration, and human pharmacokinetics are unknown. All timeline estimates are extrapolated from Russian preclinical data.
No long-term human data exists. Russian bioregulator theory suggests extended use for 'cellular regulation' but this lacks scientific validation. Safety of prolonged use is uncharacterized.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Pinealon product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Pinealon with other peptides. Based on published research and mechanistic considerations.
Epithalon
CompatibleBoth are Khavinson bioregulator peptides with different proposed targets. Epithalon focuses on telomerase activation while Pinealon targets brain function. No interaction studies available; both lack independent validation.
Semax
CompatibleDifferent mechanisms of action (Semax is ACTH-derived with BDNF modulation vs Pinealon's proposed antioxidant effects). Both target cognitive function through distinct pathways. No combined studies exist.
Cortexin
CompatibleBoth are Russian neuropeptide preparations. Cortexin is a complex polypeptide mixture while Pinealon is a defined tripeptide. Theoretical complementary effects; no interaction data available.
Selank
CompatibleNon-overlapping mechanisms. Selank modulates GABA and serotonin systems while Pinealon claims antioxidant and ERK modulation. No contraindications known; both lack rigorous human data.
BPC-157
CompatibleDifferent primary targets (Pinealon for brain, BPC-157 for tissue repair). No known interactions; both peptides lack comprehensive human pharmacokinetic data.
Dihexa
CautionBoth claimed to have cognitive effects. Dihexa has potent HGF receptor activity. Combining experimental nootropic peptides with unknown safety profiles warrants caution.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Pinealon
Pinealon Calculators
Related Peptides
Alixorexton
ALKS 2680, ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070, N-PEP-12, Renacenz
A porcine brain-derived peptide mixture approved in over 50 countries (Austria, Russia, China, Germany) for stroke, dementia, and traumatic brain injury. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. NOT FDA-approved despite decades of international use. Mixed Phase 3 results but positive meta-analyses and widespread clinical adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin, Cerebral peptides, A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Dihexa
PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide, WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.
N-Acetyl Selank Amidate
NA-Selank, N-Acetyl Selank, Acetyl-Selank-Amidate +1 more
A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.